<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-7.anc" start="3077" end="3088" sStart="2875" offset="202" sid="r11.recommend.v.0377" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="In the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI), peripheral alpha-1 antagonists are recommended not only as second-line anti-hypertensive therapy after low-dose diuretics and beta blockers, but also for specific indications such as therapy in men with hypertension and prostatism [ 2 ] . Alpha-1 antagonists represent effective therapy for prostatism, and fifty percent of men have histologic evidence of BPH by 60 years of age [ 3 4 ] . The National Ambulatory Medical Care Survey reported that the number of people on any type of peripheral alpha-1 antagonist in 1995 was approximately 6 to 7% of those with hypertension [ 5 ] . About 80% of surveyed physicians would choose these drugs as a first-line blood pressure agent for patients with hypertension and symptoms of BPH [ 6 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-7.anc" start="16434" end="16445" sStart="null" offset="112" sid="r11.recommend.v.0378" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="Not only are increased plasma catecholamines a central feature in heart failure, they are now a recommended target for effective life-prolonging therapy [ 24 25 26 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-7.anc" start="6225" end="6229" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="cgozo" text="The termination &lt;b&gt;rate&lt;/b&gt; of 13." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-7.anc" start="13371" end="13376" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="cgozo" text="The &lt;b&gt;rates&lt;/b&gt; of CHF in SHEP participants treated with diuretics and placebo were 5 and 10 per 1,000 person-years, respectively." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-7.anc" start="6225" end="6229" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="The termination &lt;b&gt;rate&lt;/b&gt; of 13." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-7.anc" start="13371" end="13376" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="The &lt;b&gt;rates&lt;/b&gt; of CHF in SHEP participants treated with diuretics and placebo were 5 and 10 per 1,000 person-years, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-7.anc" start="17098" end="17108" sStart="null" offset="29" sid="r10.particular.j.0640" wn="2147483645" wnkey="null" annotator="brubin" text="For heart failure in particular, the increase in symptomatic episodes of CHF may be due to hemodynamic effects of doxazosin unmasking incipient heart failure, direct myocardial injury, or both." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-7.anc" start="8703" end="8713" sStart="null" offset="3" sid="r10.particular.j.0854" wn="3" wnkey="particular%5:00:00:uncommon:00" annotator="anfahmy" text="In particular, peripheral alpha-1 antagonists are associated with an increase in plasma norepinephrine in diverse patient populations, as summarized in Table 3. This table reflects increases in norepinephrine in normotensive patients, hypertensive patients, and patients with chronic congestive heart failure from a variety of these small studies." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1468-6708-3-7.anc" start="12475" end="12479" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" annotator="elstickles" text="Since ALLHAT is a comparative trial, we &lt;b&gt;know&lt;/b&gt; that doxazosin is associated with more adverse cardiovascular outcomes than low-dose chlorthalidone, but we do not &lt;b&gt;know&lt;/b&gt; how doxazosin might compare with placebo." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1468-6708-3-7.anc" start="12475" end="12479" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" annotator="carichter" text="Since ALLHAT is a comparative trial, we &lt;b&gt;know&lt;/b&gt; that doxazosin is associated with more adverse cardiovascular outcomes than low-dose chlorthalidone, but we do not &lt;b&gt;know&lt;/b&gt; how doxazosin might compare with placebo." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-7.anc" start="2069" end="2080" sStart="null" offset="86" sid="r11.combination.n.0403" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Studies were included in our review if they addressed either one or a combination of the three agents as the main focus in the context of hypertension therapy and if they in some way addressed the outcomes of interest noted above." />
  </sentences>
</list>